Tuberculosis Diagnostics Market - Segmented by Diagnostic Test Type, End User and Geography - Growth, Trends, and Forecast (2018 - 2023)
The Global Tuberculosis Diagnostics Market accounted for USD 2,297.1 million in 2017 and is expected to reach USD 2,870.8 million by 2023 while witnessing a CAGR of 4.56% over the period of 2018-2023 (henceforth referred to as the forecast period). Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies.
Increasing Burden of Tuberculosis and Multidrug-Resistant Tuberculosis (MDR-TB)
According to the WHO’s 2017 Global Tuberculosis Report, approximately 6.3 million new cases of tuberculosis (TB) were reported in 2016. The report also estimated that the new cases corresponded to 61% of the estimated incidence of 10.4 million TB cases. According to WHO, the global treatment success rate in TB treatment was approximately 83%. Insights from the aforementioned report also indicate that around 10 countries account for approximately 76% of the total gap between total TB incidence and total TB reporting. The top countries contributing to this gap include India, Indonesia, and Nigeria. TB is the 9th leading cause of death worldwide according to WHO and is the leading cause of death from a single infectious agent. TB causes more deaths than HIV/AIDS. According to WHO estimates, in 2016, around 600,000 new cases of rifampicin-resistant (RR) TB were reported globally, while the number of new cases of multidrug-resistant (MDR) TB, in 2016, was estimated to be around 490,000. Approximately 50% of these new TB cases were reported in the regions of India, China, and the Russian Federation. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB, which is driving the growth of the global tuberculosis diagnostics market, supported by the increasing global prevalence of TB and MDR-TB.
High Costs Associated with Tuberculosis Diagnostics
There are tremendous improvements in both TB diagnostics and TB management in the past couple of decades. However, a major impediment to the treatment of TB is a diagnostic process that required multiple visits to the clinic to the diagnostic laboratory. TB is a more prevalent phenomenon in low-income countries and affects populations with limited resources and restricted access to health services in low and middle-income countries. In these regions, access to services is a major problem. According to WHO estimates, approximately 77 million smear investigations are conducted every year in the top twenty high burden countries for TB. Although drugs for first-line treatment for TB are provided for free by most national TB programs, the financial costs incurred by the patient and their family for diagnosis remain significant and further costs may include hospitalization, treatment of side effects, nutrition, and others. In TB, the onset of the disease often exacerbates poverty, as the patient enters a lengthy period of expenditure on health care and productivity losses. Direct costs in TB diagnosis start with the patient undertaking consultations to reach a diagnosis, yet these costs had been overlooked by policymakers, until recently. Although TB diagnostics tests are free of charge in most countries, public health services often charge patients for their initial clinical consultation, non-specific medications, and other diagnostic tests, such as X-rays. Patients must also meet the cost of displacement from home, including domestic responsibilities, subsistence, and loss of earnings. Costs are augmented by the need for patients to spend several days near the health facility to complete the tests and meet health staff for clinical management decisions. Consequently, the high cost of TB diagnosis is a hindrance to the growth of the global tuberculosis diagnostics market as it inhibits potential TB patients from undergoing diagnosis and treatment.
Under the Diagnostic Test Type segment, the largest market share in the current market is controlled by Laboratory Test, while the fastest growing segment is expected to be Nucleic Acid Testing. Under the Laboratory Test sub-segment, the larger market share is controlled by Smear Microscopy. The larger share of Smear Microscopy is due to fact that Sputum smear microscopy test has been the prime method for diagnosis of pulmonary TB in low- and middle-income countries, which is where nearly 95 % of TB cases and 98 % of deaths are occurring. The smear test is a simple, rapid, and inexpensive technique, which is highly specific in areas with a very high prevalence of tuberculosis. According to the US Department of Health and Human Services, in 2010, 43% of pulmonary TB cases in the United States were sputum smear positive. Hence, the usage of this test in the United States is more.
Under the Geography segment, Asia-Pacific region holds the largest market share. Additionally, Asia-Pacific region is also expected to be the fastest growing region over the forecast period in this market. The largest regional market in the Asia-Pacific region is expected to be the China market, while the fastest growing market is expected to be the India market. The largest share of China market, in the Asia-Pacific region, is attributable to the development of a large-scale control program in China, which is modeled on the World Health Organization's recommendations, which was implemented during 2000-2010. This program led to 750,000 TB patients receiving effective treatment each year, reducing the number of those affected, by more than 50%. Since then, the number of cases has continued to decline from 7.1 per 1 million, in 2011, to 6.3 per 1 million, in 2015, as per the National Health and Family Planning Commission. Due to better diagnosis and treatment options, it has been estimated that by 2020, the number of new TB cases will fall below 5.8 per million and that more than 90% of TB patients will receive effective medical treatment.
Key Developments in the Market
- Jun 2018 - Qiagen welcomed new guidelines from the American Academy of Pediatrics (AAP) for screening children as young as two years old, for latent tuberculosis infection.
- May 2018 - Oxford Immunotec Global PLC’s T-SPOT.TB test for tuberculosis infection was included in the first edition of the WHO model list of essential in-vitro diagnostics.
Major Players -Abbott Laboratories, Becton Dickinson & Company, BioMerieux SA, Cepheid, F. Hoffmann-La Roche AG, Hain LifeScience GmbH, Hologic Corporation, Qiagen, AdvaCare Pharma, and Thermo Fischer Scientific Inc., among others.
Reasons to Purchase the Report
- Current and future of Tuberculosis Diagnostics Market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the market estimate sheet (in Excel)
Customization of the Tuberculosis Diagnostics Market Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your need.